TAZOCIN

Tazocin Adverse Events Reported to the FDA Over Time

How are Tazocin adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Tazocin, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Tazocin is flagged as the suspect drug causing the adverse event.

Most Common Tazocin Adverse Events Reported to the FDA

What are the most common Tazocin adverse events reported to the FDA?

Liver Function Test Abnormal	52 (2.6%)
Hepatotoxicity	51 (2.55%)
Dilatation Intrahepatic Duct Acquir...	48 (2.4%)
Alanine Aminotransferase Increased	47 (2.35%)
Venoocclusive Liver Disease	33 (1.65%)
Pyrexia	29 (1.45%)
Blood Alkaline Phosphatase Increase...	28 (1.4%)
Dyspnoea	27 (1.35%)
Aspartate Aminotransferase Increase...	26 (1.3%)
Blood Bilirubin Increased	24 (1.2%)
Rash	24 (1.2%)
	Show More
Condition Aggravated	23 (1.15%)
Erythema	23 (1.15%)
Jaundice	23 (1.15%)
Septic Shock	23 (1.15%)
Thrombocytopenia	21 (1.05%)
Dermatitis Exfoliative	19 (.95%)
Malaise	19 (.95%)
White Blood Cell Count Decreased	19 (.95%)
Liver Disorder	18 (.9%)
Diarrhoea	17 (.85%)
Blood Pressure Decreased	16 (.8%)
Drug Ineffective	16 (.8%)
Hypotension	16 (.8%)
Interstitial Lung Disease	16 (.8%)
Multi-organ Failure	16 (.8%)
Blood Lactate Dehydrogenase Increas...	15 (.75%)
Hepatic Function Abnormal	15 (.75%)
Sepsis	15 (.75%)
Death	14 (.7%)
Gastroenteritis Clostridial	14 (.7%)
Renal Failure	14 (.7%)
Cyanosis	13 (.65%)
Pruritus	13 (.65%)
Blood Creatinine Increased	12 (.6%)
Hyperhidrosis	12 (.6%)
Megacolon	12 (.6%)
Nausea	12 (.6%)
Pneumonia	12 (.6%)
Toxic Epidermal Necrolysis	12 (.6%)
Venoocclusive Disease	12 (.6%)
Cardio-respiratory Arrest	11 (.55%)
Chest Pain	11 (.55%)
Chills	11 (.55%)
Clostridial Infection	11 (.55%)
Hepatic Failure	11 (.55%)
Neutropenia	11 (.55%)
Renal Failure Acute	11 (.55%)
Stevens-johnson Syndrome	11 (.55%)
Anaphylactic Reaction	10 (.5%)
Paraesthesia	10 (.5%)
Weight Decreased	10 (.5%)
Acute Respiratory Distress Syndrome	9 (.45%)
Asthenia	9 (.45%)
C-reactive Protein Increased	9 (.45%)
Cough	9 (.45%)
Depressed Level Of Consciousness	9 (.45%)
Disseminated Intravascular Coagulat...	9 (.45%)
Drug Rash With Eosinophilia And Sys...	9 (.45%)
General Physical Health Deteriorati...	9 (.45%)
Infection	9 (.45%)
Pain	9 (.45%)
Swelling Face	9 (.45%)
Toxic Skin Eruption	9 (.45%)
Vomiting	9 (.45%)
Anaemia	8 (.4%)
Blood Urea Increased	8 (.4%)
Concomitant Disease Progression	8 (.4%)
Headache	8 (.4%)
Hepatic Enzyme Increased	8 (.4%)
Loss Of Consciousness	8 (.4%)
Rash Maculo-papular	8 (.4%)
Renal Disorder	8 (.4%)
Abdominal Pain Lower	7 (.35%)
Agranulocytosis	7 (.35%)
Anaphylactic Shock	7 (.35%)
Cardiac Arrest	7 (.35%)
Gamma-glutamyltransferase Increased	7 (.35%)
Hypersensitivity	7 (.35%)
Hypophagia	7 (.35%)
Ileus Paralytic	7 (.35%)
Laryngeal Oedema	7 (.35%)
Leukopenia	7 (.35%)
Myalgia	7 (.35%)
Oxygen Saturation Decreased	7 (.35%)
Tachycardia	7 (.35%)
Drug Interaction	6 (.3%)
Eosinophil Percentage Increased	6 (.3%)
Haemoglobin Decreased	6 (.3%)
Pancytopenia	6 (.3%)
Rash Erythematous	6 (.3%)
Urticaria	6 (.3%)
Body Temperature Increased	5 (.25%)
Drug Hypersensitivity	5 (.25%)
Eosinophilia	5 (.25%)
Face Oedema	5 (.25%)
Fatigue	5 (.25%)
Granulocytopenia	5 (.25%)
Hepatitis	5 (.25%)
Histiocytosis Haematophagic	5 (.25%)
Hot Flush	5 (.25%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Tazocin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Tazocin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Tazocin

What are the most common Tazocin adverse events reported to the FDA?

Epidermal And Dermal Conditions	182 (9.1%)
Hepatobiliary	176 (8.8%)
Hepatic And Hepatobiliary	171 (8.55%)
Infections - Pathogen Unspecified	88 (4.4%)
Hematology Investigations	60 (3%)
Respiratory	58 (2.9%)
Bacterial Infectious	57 (2.85%)
Enzyme	49 (2.45%)
Bile Duct	48 (2.4%)
White Blood Cell	47 (2.35%)
Renal Disorders	46 (2.3%)
	Show More
Neurological	44 (2.2%)
Gastrointestinal Signs	40 (2%)
Gastrointestinal Motility And Defec...	36 (1.8%)
Body Temperature Conditions	34 (1.7%)
Allergic Conditions	33 (1.65%)
Lower Respiratory Tract Disorders	33 (1.65%)
Cardiac Arrhythmias	29 (1.45%)
Renal And Urinary Tract Investigati...	28 (1.4%)
Therapeutic And Nontherapeutic Effe...	28 (1.4%)
Platelet	24 (1.2%)
Vascular	23 (1.15%)
Anemias Nonhemolytic And Marrow Dep...	20 (1%)
Cardiac And Vascular Investigations	20 (1%)
Decreased And Nonspecific Blood Pre...	20 (1%)
Movement Disorders	16 (.8%)
Upper Respiratory Tract Disorders	16 (.8%)
Cardiac Disorder Signs	15 (.75%)
Muscle	15 (.75%)
Physical Examination Topics	15 (.75%)
Coagulopathies And Bleeding Diathes...	14 (.7%)
Fatal Outcomes	14 (.7%)
Protein And Chemistry Analyses	13 (.65%)
Metabolic, Nutritional And Blood Ga...	12 (.6%)
Seizures	12 (.6%)
Skin Appendage Conditions	12 (.6%)
Angiedema And Urticaria	10 (.5%)
Appetite And General Nutritional	10 (.5%)
Bronchial Disorders	9 (.45%)
Oral Soft Tissue Conditions	9 (.45%)
Water, Electrolyte And Mineral	9 (.45%)
Electrolyte And Fluid Balance Condi...	8 (.4%)
Fungal Infectious	8 (.4%)
Headaches	8 (.4%)
Procedural And Device Related Injur...	8 (.4%)
Viral Infectious	8 (.4%)
Medication Errors	7 (.35%)
Neuromuscular	7 (.35%)
Bone And Joint Injuries	6 (.3%)
Hematological And Lymphoid Tissue T...	6 (.3%)
Injuries	6 (.3%)
Ocular Infections, Irritations And ...	6 (.3%)
Skin Vascular Abnormalities	6 (.3%)
Urinary Tract Signs	6 (.3%)
Central Nervous System Vascular	5 (.25%)
Gastrointestinal Hemorrhages	5 (.25%)
Hematopoietic Neoplasms	5 (.25%)
Musculoskeletal And Connective Tiss...	5 (.25%)
Administration Site Reactions	4 (.2%)
Cognitive And Attention Disorders	4 (.2%)
Disturbances In Thinking	4 (.2%)
Eye	4 (.2%)
Increased Intracranial Pressure And...	4 (.2%)
Joint	4 (.2%)
Mental Impairment	4 (.2%)
Tongue Conditions	4 (.2%)
Vascular Hypertensive	4 (.2%)
Chemical Injury And Poisoning	3 (.15%)
Cornification And Dystrophic Skin	3 (.15%)
Coronary Artery	3 (.15%)
Cranial Nerve Disorders	3 (.15%)
Deliria	3 (.15%)
Encephalopathies	3 (.15%)
Gastrointestinal Inflammatory Condi...	3 (.15%)
Gastrointestinal Ulceration And Per...	3 (.15%)
Hemolyses And Related Conditions	3 (.15%)
Immune	3 (.15%)
Myocardial	3 (.15%)
Product Quality Issues	3 (.15%)
Respiratory Disorders Congenital	3 (.15%)
Structural Brain	3 (.15%)
Therapeutic Procedures And Supporti...	3 (.15%)
Toxicology And Therapeutic Drug Mon...	3 (.15%)
Acid-base	2 (.1%)
Anal And Rectal Conditions	2 (.1%)
Aural	2 (.1%)
Gallbladder	2 (.1%)
Leukemias	2 (.1%)
Mycoplasmal Infectious	2 (.1%)
Ocular Hemorrhages And Vascular	2 (.1%)
Peripheral Neuropathies	2 (.1%)
Peritoneal And Retroperitoneal Cond...	2 (.1%)
Psychiatric And Behavioural Symptom...	2 (.1%)
Respiratory And Mediastinal Neoplas...	2 (.1%)
Sleep Disorders	2 (.1%)
Spleen, Lymphatic And Reticulendoth...	2 (.1%)
Vascular Hemorrhagic	2 (.1%)
Anxiety Disorders	1 (.05%)
Arteriosclerosis, Stenosis, Vascula...	1 (.05%)
Bone Disorders	1 (.05%)
Cardiac Valve	1 (.05%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Tazocin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Tazocin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.